Malignant mixed Mullerian tumors of the uterus: Histopathological evaluation of cell cycle and apoptotic regulatory proteins

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Kanthan, Rani ^a   Senger, Jenna Lynn B ^a   Diudea, Dana ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN EMA; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN PCNA; TUMOR MARKER; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIXED MULLERIAN TUMOR; PROTEIN EXPRESSION; UTERUS TUMOR; ENZYME IMMUNOASSAY; FEMALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; UTERINE CERVIX TUMOR;

AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM METASTASIS; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 77954668790     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-60     Document Type: Article

References (73)

1. Nguyen CP, Levi AW, Montz FJ, Bristow RE. Coexistent Choriocarcinoma and Malignant Mixed Mesodermal Tumor of the Uterus. Gynecol Oncol 2000, 79(3):499-503. 10.1006/gyno.2000.5976, 11104628.
2. Robinson-Bennett B, Belch RZ, Han AC. Loss of p16 in Recurrent Malignant Mixed Mullerian Tumors of the Uterus. International Journal of Gynecological Cancer 2006, 16(3):1354-7. 10.1111/j.1525-1438.2006.00411.x, 16803529.
3. De Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol 1993, 24(2):132-142. 10.1016/0046-8177(93)90291-N, 7679366.
4. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, Miller A. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology group pathologic study of 203 cases. Int Gynaecol Pathol 1990, 9(1):1-19.
5. Iwasa Y, Haga H, Konishi I, Kobashi Y, Higuchi K, Katsuyama E, Minamiguchi S, Yamabe H. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer 1998, 82(3):512-9. 10.1002/(SICI)1097-0142(19980201)82:3<512::AID-CNCR13>3.0.CO;2-4, 9452269.
6. Clement PB, Scully RE. Mullerian Adenosarcoma of the Uterus: A Clinicopathologic Analysis of 100 Cases With a Review of the Literature. Hum Pathol 1990, 21(4):363-381. 10.1016/0046-8177(90)90198-E, 2156771.
7. Blom R, Guerrieri C, Stal O, Malmstrom H, Sullivan S, Simonsen E. Malignant mixed Mullerian tumors of the uterus: a clinicopathologic DNA flow cytometric p53, and mdm-2 analysis of 44 cases. Gynecol Oncol 1998, 68(1):18-24. 10.1006/gyno.1997.4892, 9454654.
8. Yoshida Y, Kurokawa T, Fukuno N, Nishikawa Y, Kamitani N, Kotsuji F. Markers of Apoptosis and Angiogenesis Indicate That Carcinomatous Components Play an Important Role in the Malignant Behavior of Uterine Carcinosarcoma. Hum Pathol 2000, 31(12):1448-1454. 10.1053/hupa.2000.20372, 11150369.
9. Navarini R, Pineda RL. Malignant mixed mullerian tumors of the ovary. Current Opinion in Obstetrics and Gynecology 2006, 18(1):20-23. 10.1097/01.gco.0000192997.27663.9e, 16493255.
10. Yuan Y, Kim WH, Han HS, Lee JH, Park HS, Chung JK, Kang SB, Park JG. Establishment and Characterization of Cell Lines Derived from Uterine Malignant Mixed Mullerian Tumor. Gynecol Oncol 1997, 66(3):464-474. 10.1006/gyno.1997.4802, 9299262.
11. Nicotina PA, Ferlazzo G, Vincelli AM. Proliferation indices and p53-immunocytochemistry in uterine mixed mullerian tumors. Histol Histopathol 1997, 12(4):967-72.
12. Pushkar I, Rao U. Final Diagnosis - Mixed Mullerian Tumors. Retrieved on June 1, 2009.., http://path.upmc.edu/cases/case227/dx.html
13. Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role for the epithelial component and the conversion theory of histogenesis. American Journal of Surgical Pathology 1995, 19(6):666-74. 10.1097/00000478-199506000-00007, 7755153.
14. Jin Z, Ogata S, Tamura G, Katayama Y, Fukase M, Yajima M, Motoyama T. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. International Journal of Gynaecological Pathology 2003, 22(4):368-73.
15. Conner MG. Uncommon and Relatively Uncommon Lesions of the Female Reproductive System. Advances in Experimental Medicine and Biology 2005, 563:10-20. full_text, 16433118.
16. Abeln EC, Smit VT, Wessels JW, de Leeuw WJ, Cornelisse CJ, Fleuren GJ. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumors. J Pathol 1997, 183(4):424-31. 10.1002/(SICI)1096-9896(199712)183:4<424::AID-PATH949>3.0.CO;2-L, 9496259.
17. Sebenik M, Yan Z, Khalbuss WE, Mittal K. Malignant Mixed Mullerian Tumor of the Vagina: Case Report with Review of the Literature Immunohistochemical Study and Evaluation for Human Papilloma Virus. Human Pathology 2007, 38(8):1282-1288. 10.1016/j.humpath.2007.03.008, 17640554.
18. Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Sato S, Terakawa N. Chemotherapy Consisting of Paclitaxel and Carboplatin Benefits a Patient with Malignant Mixed Mullerian Tumor of the Fallopian Tube. International Journal of Clinical Oncology 2008, 13(5):461-3. 10.1007/s10147-008-0767-1, 18946759.
19. Handa Y, Kato H, Kaneuchi M, Saitoh Y, Yamashita K. High-grade Broad Ligament Cancer of Mullerian Origin: Immunohistochemical Analysis of a Case and Review of the Literature. International Journal of Gynecological Cancer 2007, 17(3):705-734. 10.1111/j.1525-1438.2007.00843.x, 17504384.
20. Maitra RN, Lee J, McConnell DT, Kenwright DN, Dady P. Malignant Mixed Mullerian Tumour of the Fallopian Tube Occuring in a Patient with Peutz-Jegher's Syndrome. Australian and New Zealand Journal of Obstetrics and Gynaecology 2004, 44(1):77-79. 10.1111/j.1479-828X.2004.00166.x, 15089876.
21. Mok JE, Kim YM, Jung MH, Kim KR, Kim DY, Kim JH, Kim YT, Nam JH. Mixed Mullerian Tumors of the Ovary: Experience with Cytoreductive Surgery and Platinum-Based Combination Chemotherapy. International Journal of Gynarcological Cancer 2006, 16(1):101-5.
22. Moe MM, El-Sharkawi S. Is There Any Association Between Uterine Malignant Mixed Mullerian Tumor Breast Cancer and Prolonged Tamoxifen Treatment?. Journal of Obstetrics and Gynaecology 2003, 23(3):301-3. 10.1080/01443610310000100150, 12850867.
23. Wang X, Tangjitgamol S, Liu J, Kavanagh JJ. Response of Recurrent Uterine High-Grade Malignant Mixed Mullerian Tumor to Letrozole. International Journal of Gynaecological Cancer 2005, 15(5):1243-8.
24. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant Mixed Mullerian Tumors of the Uterus: Analysis of Patterns of Failure Prognostic Factors and Treatment Outcome. International Journal of Radiation Oncology Biology, Physics 2004, 58(3):786-96.
25. Maheshwari A, Gupta S, Shet T, Wuntkal R, Tongaonkar HB. Diagnostic dilemma in a case of malignant mixed mullerian tumor of the cervix. World Journal of Surgical Oncology 2006, 4:36. 10.1186/1477-7819-4-36, 1526432, 16813659.
26. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR. Uterine Malignant Mixed Mullerian Tumors Should not be Included in Studies of Endometrial Carcinoma. Gynecologic Oncology 2006, 103(2):684-7. 10.1016/j.ygyno.2006.05.009, 16797683.
27. Mikami M, Kuwabara Y, Tanaka K, Komiyama S, Ishikawa M, Hirose T. Malignant Mixed Mullerian Tumor of Primary Mesenteric Origin. International Journal of Gynarcological Cancer 2005, 15(6):1249-1253.
28. DiSaia PJ, Castro JR, Rutledge FN. Mixed mesodermal sarcoma of the uterus. Am J Roentgenol 1973, 117(3):632-636.
29. Hoskins PJ, Le N, Ellard S, Lee U, Martin LA, Swenerton KD, Tinker AV, . British Columbia Cancer Agency Carboplatin plus Paclitaxel for Advanced or Recurrent Uterine Malignant Mixed Mullerian Tumors. The British Columbia Cancer Agency Experience. Gynecologic Oncology 2008, 108(1):58-62. 10.1016/j.ygyno.2007.08.084, 17935761, British Columbia Cancer Agency.
30. Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, Greer BE, Muntz HG, Goff BA. The Expression of Epidermal Growth Factor Receptor HER-2/Neu, p53, and Ki-67 Antigen in Uterine Malignant Mixed Mesodermal Tumors and Adenosarcoma. Gynecol Oncol 1996, 60(1):81-88. 10.1006/gyno.1996.0015, 8557233.
31. Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P, Finkelstein SD. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998, 29(1):82-7. 10.1016/S0046-8177(98)90394-X, 9445138.
32. Bur ME, Perlman C, Edelmann L, Fev E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992, 98(1):81-7.
33. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992, 140(1):145-153. 1886248, 1731521.
34. Gagner JP, Mittal K. Malignant Mixed Mullerian Tumor of the Fimbriated End of the Fallopian Tube: Origin as an Intraepithelial Carcinoma. Gynecologic Oncology 2005, 97(1):219-222. 10.1016/j.ygyno.2004.11.053, 15790462.
35. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. p53 Expression as a Prognostic Indicator of 5-Year Survival in Endometrial Cancer. Gynecol Oncol 1999, 74(3):468-471. 10.1006/gyno.1999.5482, 10479512.
36. Liu FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. Mutation and Overexpression of the p53 Tumor Suppressor Gene Frequently Occurs in Uterine and Ovarian Sarcomas. Obs and Gynecol 1994, 83(1):118-123.
37. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993, 85(18):1513-9. 10.1093/jnci/85.18.1513, 8360934.
38. Costa MJ, Vogelsan J, Young LJ. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): a clinicopathologic study of 74 cases. Mod Pathol 1994, 7(6):619-27.
39. Toffoli G, Doglioni C, Cernigoi C, Frustaci S, Perin T, Canal B, Boiocchi M. p53 overexpression in human soft tissue sarcomas: Relation to biological aggressiveness. Ann Oncol 1994, 5(2):167-172.
40. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994, 170(1 Pt 1):246-252.
41. Huang LW, Chou YY, Chao SL, Chen TJ, Lee TT. p53 and p21 Expression in Precancerous Lesions and Carcinomas of the Uterine Cervix: Overexpression of p53 Predicts Poor Disease Outcome. Gynecol Oncol 2001, 83(2):348-354. 10.1006/gyno.2001.6397, 11606096.
42. Soong R, Knowles S, Hammond IG, Michael C, Lacopetta BJ. P53 protein overexpression and gene mutation in mixed Mullerian tumors of the uterus. Cancer Detect Prev 1999, 23(1):8-12. 10.1046/j.1525-1500.1999.00062.x, 9892985.
43. Holst VA, Finkelstein S, Colby TV, Myers JL, Yousem SA. p53 and K-ras mutational genotyping in pulmonary carcinosarcoma spindle cell carcinoma and pulmonary blastoma: implications for histogenesis. Am J Surg Pathol 1997, 21(7):801-11. 10.1097/00000478-199707000-00008, 9236836.
44. Palmqvist R, Rutegard JN, Bozoky B, Landberg G, Stenling R. Human Colorectal Cancers with an Intact p16/Cyclin D1/pRb Pathway Have Up-Regulated p16 Expression and Decreased Proliferation in Small Invasive Tumor Clusters. Am J Path 2000, 157(6):1947-53.
45. Milde-Langosch K, Riethdorf L, Bamberger AM, Loning T. P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch 1999, 434(1):23-8. 10.1007/s004280050300, 10071231.
46. Ramirez PT, Gershenson DM, Tortolero-Luna G, Ramondetta LM, Fightmaster D, Wharton JT, Wolf JK. Expression of Cell-Cycle Mediators in Ovarian Cancer Cells after Transfection with p16, p21, and p53. Gynecol Oncol 2001, 83(3):543-548. 10.1006/gyno.2001.6438, 11733969.
47. Munirajan AK, Kannan K, Bhuvarahamurthy V, Ishida I, Fujinaga K, Tsuchida N, Shanmugam G. The Status of Human Papillomavirus and Tumor Suppressor Genes p53 and p16 in Carcinomas of Uterine Cervix from India. Gynecol Oncol 1998, 69(3):205-209. 10.1006/gyno.1998.4991, 9648588.
48. Shapiro GI, Edwards CD, Ewen ME, Rollins BJ. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 1998, 18(1):378-387. 121508, 9418885.
49. Dimitrakakis C, Kymionis G, Diakomanolis E, Papaspyrou I, Rodolakis A, Arzimanoglou I, Leandros E, Michalas S. The Possible Role of p53 and bcl-2 Expression in Cervical Carcinomas and Their Premalignant Lesions. Gynecol Oncol 2000, 77(1):129-136. 10.1006/gyno.1999.5715, 10739702.
50. Thompson C. Apoptosis in the Pathogenesis and Treatment of Disease. Science 1995, 267(5203):1457-1461.
51. Soini Y, Paakko P, Lehto VP. Histopathological Evaluation of Apoptosis in Cancer. Am J Pathol 1998, 153(4):1041-1051. 1853067, 9777936.
52. Kerr JF, Winterford CM, Harmon BV. Apoptosis - Its Significance in Cancer and Cancer Therapy. Cancer 1994, 73(8):2013-2023. 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J, 8156506.
53. Alnemri ES, Fernandes TF, Haldar S, Croce CM, Litwack G. Involvement of bcl-2 in Glucocorticoid-Induced Apoptosis of Human Pre-B-Leukemias. Cancer Res 1992, 52(2):491-5.
54. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A Link between Cancer Genetics and Chemotherapy. Cell 2002, 108(2):153-164. 10.1016/S0092-8674(02)00625-6, 11832206.
55. Domen J, Gandy KL, Weissman IL. Systemic Overexpression of Bcl-2 in the Hematopoietic System Protects Transgenic Mice from the Consequences of Lethal Irradiation. Blood 1998, 91(7):2272-2282.
56. Adams JM, Cory S. The Bcl-2 Protein Family: Arbiters of Cell Survival. Science 1998, 281(5381):1322-1326. 10.1126/science.281.5381.1322, 9735050.
57. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: Coregulation of Dimer Formation and Intracellular Localization. Cell 2000, 103(4):645-653. 10.1016/S0092-8674(00)00167-7, 11106734.
58. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. Lack of Bcl-2 Persistence: an Independent Prognostic Indicator of Poor Prognosis in Endometrial Carcinoma. Gynecol Oncol 1998, 71(2):305. 10.1006/gyno.1998.5192, 9826476.
59. Crescenzi E, Palumbo G. Bcl-2 Exerts a pRb-Mediated Cell Cycle Inhibitory Function in HEC1B Endometrial Carcinoma Cells. Gynecol Oncol 2001, 81(2):184-192. 10.1006/gyno.2001.6128, 11330947.
60. Nakamura T, Nomura S, Sakai T, Nariya S. Expression of bcl-2 Oncoprotein in Gastrointestinal and Uterine Carcinomas and their Premalignant Lesions. Hum Pathol 1997, 28(3):309-15. 10.1016/S0046-8177(97)90129-5, 9042795.
61. Yang HB, Chow NH, Sheu BS, Chan SH, Chien CH, Su IJ. The Role of Bcl-2 in the Progression of the Colorectal Adenoma-Carcinoma Sequence. Anticancer Res 1999, 19(1B):727-30.
62. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated Expression of Bcl-X and Reduced Bak in Primary Colorectal Adenocarcinomas. Cancer Res 1996, 56(10):2422-7.
63. Muller W, Schneiders A, Hommel G, Gabbert HE. Prognostic Value of Bcl-2 Expression in Gastric Cancer. Anticancer Res 1998, 18(6B):4699-704.
64. Crescenzi E, Criniti V, Pianese M, Tecce MF, Palumbo G. Differential Expression of Antiapoptotic Genes in Human Endometrial Carcinoma: bcl-XL Succeeds bcl-2 Function in Neoplastic Cells. Gynecol Oncol 2000, 77(3):419-428. 10.1006/gyno.2000.5803, 10831353.
65. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 Heterodimerizes in vivo with a Conserved Homologue Bax, that Accelerates Programmed Cell Death. Cell 1993, 74:609-619. 10.1016/0092-8674(93)90509-O, 8358790.
66. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 Family Members and the Mitochondria in Apoptosis. Genes Dev 1999, 13(15):1899-1911. 10.1101/gad.13.15.1899, 10444588.
67. Kokawa K, Shikone T, Otani T, Nishiyama R, Ishii Y, Yagi S, Yamoto M. Apoptosis and the Expression of Bcl-2 and Bax in Patients with Endometrioid Clear Cell and Serous Carcinomas of the Uterine Endometrium. Gynecol Oncol 2001, 81(2):178-183. 10.1006/gyno.2001.6138, 11330946.
68. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. The Bax Gene the Promoter of Apoptosis is Mutated in Genetically Unstable Cancers of the Colorectum Stomach, and Endometrium. Clin Cancer Res 1998, 4(4):1071-4.
69. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53AIP1, a Potential Mediator of p53-Dependent Apoptosis and Its Regulation by Ser-46-Phosphorylated p53. Cell 2000, 102(6):849-862. 10.1016/S0092-8674(00)00073-8, 11030628.
70. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80(2):293-299. 10.1016/0092-8674(95)90412-3, 7834749.
71. Xu ZW, Friess H, Buchler M, Solioz M. Overexpression of Bax Sensitizes Human Pancreatic Cancer Cells to Apoptosis Induced by Chemotherapeutic Agents. Cancer Chemother Pharmacol 2002, 49(6):504-10. 10.1007/s00280-002-0435-5, 12107556.
72. Hanaoka T, Nakayama J, Haniuda M, Sato TA. Immunohistochemical Demonstration of Apoptosis-Regulated Proteins Bcl-2 and Bax in Resected Non-Small-Cell Lung Cancers. Int J Clin Oncol 2002, 7(3):152-8. 10.1007/s101470200022, 12109516.
73. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ. Combined Adjuvant Cisplating and Ifosfamide Chemotherapy and Radiotherapy for Malignant Mixed Mullerian Tumors of the Uterus. International Journal of Gynaecological Cancer 2006, 16(3):1364-9.